Abstract
Valbenazine (Ingrezza®) is an orally bioavailable, selective and reversible vesicular monoamine transporter 2 (VMAT2) inhibitor that is indicated for the once-daily treatment of adults with tardive dyskinesia (TD) in the USA. By inhibiting VMAT2, thereby interfering with the presynaptic uptake and storage of dopamine and other monoamines, valbenazine is thought to counteract the heightened postsynaptic dopaminergic activity that is believed to cause TD. In adults with dopamine-receptor blocking agent-induced TD and underlying schizophrenia, schizoaffective disorder or mood disorder, valbenazine was associated with rapid, significant and sustained on-treatment improvements in TD severity relative to placebo. Somnolence is the most common treatment-emergent adverse event associated with valbenazine and, importantly, depression and extrapyramidal symptoms have not been associated with its use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
